My name is Antia Zavanna-Sanka. I'm a hematologist at Indiana University Cancer Center, and I'm presenting the data on behalf of my co-authors on the study called LYNGFRMM1, which is a study exploring an agent called lymosyltomab in patients with relapsed refractory multiple myeloma. Lymosyltomab is a bispecific monoplonal antibody that engage BCMA on the surface of the tumor cells and CD3 on the surface of the T cells. This is a phase 1-2 study that explores its efficacy in patients with relapsed refractory multiple myeloma who have at least been treated with three prior lines of therapy and also a triple class exposed. What that means is that they have been treated with agents in the family of immunomodulatory agents such as lenolidomide and proteasome inhibitors such as Brutysamab as well as monoplonal antibody such as daratumumab. We're reporting the study in the unique high risk subgroups including patients for 75 years and above, patients with high risk of the genetics, advanced stage ISS3 and also patients with extra medullary disease. So in this group of high risk patients, they have been projected to have less chance of overall response and less durability response. In all four groups of patients, the response rate to lenovaceltumab is approaching 70% except the extra medullary disease subgroup which has a little lower response rate, 56%. So still more than half. The significant key point of the study though is this response continued to be deep and durable. Now that with Alaska and off in January 2024, we're having progression free survival that's not reached in all of the groups except for the extra medullary subgroup. We project that at one year patients would continue to be in remission for nearly 80% in all subgroup and again the extra medullary subgroup actually has a shorter progression free survival. How do people fare when they're on treatment for a longer time? Early on, side effects such as cytokine release syndrome and neurotoxicity occur and they have already been reported in our full study. In these unique high risk subgroups, the incidence of the cytokine release syndrome and also the neurotoxicity did not differ comparing to the overall cohort. The ongoing follow-up show that occurring side effects that lead to treatment discontinuation is rare. The most common ones though are still infection. On the study, patients were allowed to be on prophylactic antimicrobial agents as well as the usage of the infusion of immunoglobulin called IVIG. There was about 64% usage of such infusion. We're delighted to see that patients are still able to continue to enjoy deep remission without cumulative side effects. So I think lymphocytoma is one of the novel bispecific antibodies that we hope to be able to see it expand into usage in other patient populations either alone or in combination.
HealthTree • October 8, 2024